Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection

J Hepatol. 2022 Oct;77(4):1215-1217. doi: 10.1016/j.jhep.2022.06.024. Epub 2022 Jul 5.
No abstract available

Keywords: Hepatitis C; non-responders; sofosbuvir; velpatasvir; voxilaprevir.

Publication types

  • Letter

MeSH terms

  • Aminoisobutyric Acids
  • Antiviral Agents / therapeutic use
  • Benzimidazoles
  • Benzopyrans
  • Carbamates
  • Cyclopropanes
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C, Chronic* / drug therapy
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use
  • Humans
  • Lactams, Macrocyclic
  • Leucine / analogs & derivatives
  • Proline / analogs & derivatives
  • Quinoxalines
  • Sofosbuvir* / therapeutic use
  • Sulfonamides

Substances

  • Aminoisobutyric Acids
  • Antiviral Agents
  • Benzimidazoles
  • Benzopyrans
  • Carbamates
  • Cyclopropanes
  • Heterocyclic Compounds, 4 or More Rings
  • Lactams, Macrocyclic
  • Quinoxalines
  • Sulfonamides
  • voxilaprevir
  • Proline
  • Leucine
  • velpatasvir
  • Sofosbuvir